APPARENT IC-MPGN
To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months of treatment
Why this Research Matters
Assess efficacy and safety of iptacopan compared to placebo and standard of care in adults and adolescents (12-17) with IC-MPGN in native Kidneys
Who can Participate
Age 12-60 at screening, diagnosis of idiopathic IC-MPGN by biopsy within 12 months for adults and within 3 years for adolescents. UPCR >1.0g/g, estimated GFR >= 30 ml/min/1.73m2 at screening, and up to date on vaccines
Study ID
Protocol Number: 23-0839
More information available at ClinicalTrials.gov: NCT05755386
Meet the Team
Principal Investigator